Announced Fri, 10 Jul · 16:41 IST
Routine SEBI compliance filing for Q1 FY27 from Marksans Pharma
Compliance View source PDF
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹271.85
prior close
₹270.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.9-0.6-0.6-0.3+1.6+1.1-2.0-2.0-10.9————
Up moveDown movePending
AI summary
Marksans Pharma submitted a certificate under SEBI Regulation 74(5) for Q1 FY27 (Apr-Jun 2026). The certificate from Bigshare Services, the company's Registrar and Transfer Agent, confirms that no dematerialisation requests for equity shares were received during the quarter. This is a routine procedural compliance filing required of all listed companies and has no material impact on the business or shareholders.
Likely market impact
Routine regulatory compliance filing with no material impact on business, financials, or shareholders.